Observational Study to Evaluate the Safety of Levemir® in Diabetes

Novo Nordisk A/S2,282 enrolled

Overview

This observational study is conducted in North America. The aim of this observational study is to evaluate the incidence of adverse events while using Levemir® under normal clinical practice conditions.

Study Type

OBSERVATIONAL

Enrollment

2,282

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

insulin detemirDRUG

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Type 1 or 2 diabetes * Including newly diagnosed not on insulin or insulin analogue treatment * Selection at the discretion of the physician * Adult patients with type 1 and 2 diabetes mellitus, and type 1 patients 6 years and older Exclusion Criteria: * Current treatment with Levemir® * Previously enrolled in the study * Hypersensitivity to Levemir®

Locations (1)

Novo Nordisk Investigational Site

Mexico City, Mexico

Outcomes

Primary Outcomes

Incidence of SADR (serious adverse drug reactions ) incl major hypo (hypoglycaemic events)

Time frame: during treatment

Secondary Outcomes

Glucose control measures

Time frame: during treatment

Weight

Time frame: during treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.